Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 21.8
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Hubei Goto Biopharm Co.,Ltd. engages in the production and sale of steroid hormone API's and intermediates in China. It offers starting materials, such as 9a-hydroxy-4-androstenedione(9a-OHAD), bisnoralcohol(BA), sitolactone, 1.4-androstadienedione(ADD), and 4-androstenedione(4-AD); intermediates, including estrogens, progesterone, nonsteroids, other hormones, and corticosteroids; and other pharmaceutical raw materials. The company was founded in 2006 and is based in Yicheng, China.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.
Data is available to registered users only
Buy
Sell